Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887468 | 0.89 | CYP2C19 (0.45) | CYP2C19MAPTKCNH2PLK1CYP19A1 | |
| SCHEMBL2888761 | 0.79 | CYP2C19 (0.42) | CYP2C19CYP3A4MAPK1MAPTKCNH2 | |
| SCHEMBL2886797 | 0.78 | CYP2C19 (0.47) | CYP2C19MAPTKCNH2PLK1 | |
| SCHEMBL11511380 | 0.78 | CYP3A4 (0.63) | CYP2C19CYP3A4MAPK1MAPTTSHR | |
| SCHEMBL10034408 | 0.74 | CYP2C19 (0.52) | CYP2C19CYP3A4MAPK1MAPTKCNH2 | |
| SCHEMBL2883171 | 0.74 | MAPT (0.40) | CYP3A4MAPT | |
| SCHEMBL2488807 | 0.74 | CYP2C19 (0.50) | CYP2C19CYP3A4MAPK1MAPTKCNH2 | |
| SCHEMBL2890931 | 0.73 | KCNH2 (0.50) | CYP2C19CYP3A4MAPK1MAPTKCNH2 | |
| SCHEMBL2883498 | 0.73 | CYP2C19 (0.68) | CYP2C19KCNH2 | |
| SCHEMBL18517038 | 0.72 | CYP2C19 (0.50) | CYP2C19CYP3A4MAPK1MAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440842-B2 | Antimicrobial compounds, their synthesis and their use for treatment of mammalian infections | LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNOELL-INSTITUT (DE) | 2013-05-14 | — | — | US | claimed |
| US-20100286130-A1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS | LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNOELL-INSTITUT (DE) | 2010-11-11 | — | — | US | claimed |
| EP-2176248-B1 | NEW ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS | LEIBNIZ INST NATURSTOFF FORSCH (DE) | 2010-09-29 | — | — | EP | claimed |
| US-8440842-B2 | Antimicrobial compounds, their synthesis and their use for treatment of mammalian infections | LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNOELL-INSTITUT (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20100286130-A1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS | LEIBNIZ-INSTITUT FUER NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNOELL-INSTITUT (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2176248-B1 | NEW ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS | LEIBNIZ INST NATURSTOFF FORSCH (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2020406-A1 | New antimicrobial compounds, their synthesis and their use for treatment of mammalian infection | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut (DE) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286130-A1 | ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND THEIR USE FOR TREATMENT OF MAMMALIAN INFECTIONS | ARG1, ARG2, LPO | CYP2C19 1786/4885CYP3A4 1465/4885MAPK1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.